Evidence map›Paper›PMID 40437743›Full record

ArticleMolecular oncology2025

Molecular imaging predicts trastuzumab-deruxtecan (T-DXd) response in head and neck cancer xenograft models.

Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Quantitative Spatial Profiling of Antibody Delivery and Target Engagement Using Optically Labeled Antibodies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdullah Bin NaveedDepartment of Otolaryngology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-0237-5434
Lucas ManiDepartment of Otolaryngology, Vanderbilt University, Nashville, TN, USA.
Muhammad Bilal MirzaDepartment of Surgery, Vanderbilt University, Nashville, TN, USA.
Ashtyn McAdooDepartment of Otolaryngology, Vanderbilt University, Nashville, TN, USA.
Takahito KondoDepartment of Otolaryngology, Vanderbilt University, Nashville, TN, USA.
Hidenori TanakaDepartment of Otolaryngology, Vanderbilt University, Nashville, TN, USA.
Nicole MeeksDepartment of Otolaryngology, Vanderbilt University, Nashville, TN, USA.
Eben RosenthalDepartment of Otolaryngology, Vanderbilt University, Nashville, TN, USA.
Marisa HomDepartment of Otolaryngology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0003-1319-5110

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erb-b2 receptor tyrosine kinase 2 (ERBB2; also known as HER2) expression is observed in 25-40% of head and neck squamous cell carcinomas (HNSCC), yet there are no anti-HER2 therapies under evaluation for HNSCC, as conventional cytostatic anti-HER2 antibodies have had limited effectiveness and levels of HER2 overexpression are lower in HNSCC tumors compared to breast cancer. Trastuzumab-deruxtecan (T-DXd; Enhertu) is a HER2-targeting antibody-drug conjugate (ADC) comprising an anti-HER2 monoclonal antibody, a cleavable linker, and a potent topoisomerase I inhibitor payload, and has shown promising results in very low HER2-expressing tumors. We compare the efficacy of T-DXd, trastuzumab-emtansine (ADC comprising an anti-HER2 antibody and microtubule inhibitor, T-DM1; Kadcyla) and trastuzumab (Herceptin) therapy in HNSCC with low and absent HER2 expression in vitro and in vivo. In vitro treatment of a low HER2-expressing human HNSCC cell line (FaDu) with T-DXd resulted in dose-dependent cell death (IC50 values of 9856 ng·mL

Indexed as

CamptothecinHead and Neck NeoplasmsImmunoconjugatesMolecular ImagingTrastuzumabAnimalsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansMiceMice, NudeSquamous Cell Carcinoma of Head and NeckXenograft Model Antitumor AssaysCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabtrastuzumab deruxtecanantibody‐drug conjugatesdrug deliveryErb‐b2 receptor tyrosine kinase 2head and neck squamous cell carcinomamice xenograftoptical imaging

Identifiers

PMID40437743
PMCPMC12591327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.